References
- Roxby P. ‘JN.1 Covid variant: WHO charts its rapid global spread’ (2023). https://www.bbc.com/news/health-67772390
- Reuters. CDC says JN.1 variant accounts for 39%–50% of COVID cases in US (2023). https://www.reuters.com/world/us/cdc-says-jn1-variant-accounts-39-50-covid-cases-us-2023-12-22/
- Centre for Disease Control and Prevention. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC (2023). https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html
- World Health Organization. Executive Summary and Risk Evaluation of JN.1 (2023). https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3#:∼:text=Based%20on%20its%20genetic%20features,currently%20circulating%20Omicron%20descendent%20lineages
- Kaku Y, Okumura K, Padilla-Blanco M et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. bioRxiv (2023). https://www.biorxiv.org/content/10.1101/2023.12.08.570782v1
- Schaecher SR, Mackenzie JM, Pekosz A. The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles. J. Virol. 81(2), 718–731 (2007).
- Jeworowski LM, Mühlemann B, Walper F et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Euro Surveill. 29(2), 1–6 (2024).
- Yang S, Yu Y, Xu Y et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24(2), e70–e72 (2024).
- Wang Q, Li Z, Guo Y et al. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 26(11), 108254 (2023).
- Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21(8), 475–484 (2021).
- Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vac. 6(1), 104 (2021).
- Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers. Elife 9, 1–15 (2020).
- Lambrou AS, South E, Ballou ES et al. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.2.86 — Worldwide, July–October 2023. MMWR Morb. Mortal. Wkly Rep. 72(43), 1162–1167 (2023).
- Morens DM, Taubenberger JK, Fauci AS. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31(1), 146–157 (2023).
- Centre for Disease Control and Prevention. ‘Updated COVID Vaccines and the JN.1 Variant’ (2024). https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/why-do-vaccines-need-to-get-updated/#/+/0/publishedDate_na_dt/desc/
- Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of Phase III candidates. NPJ Vac. 6(1), 28 (2021).
- Uttamrao PP, Sathyaseelan C, Patro LPP, Rathinavelan T. Revelation of potent epitopes present in unannotated ORF antigens of SARS-CoV-2 for epitope-based polyvalent vaccine design using immunoinformatics approach. Front. Immunol. 12, 1–13 (2021).
- Rubin R. Challenges of deciding whether and how to update COVID-19 vaccines to protect against variants. JAMA 327(23), 2273 (2022).
- Basu S, Ashok G, Debroy R, Ramaiah S, Livingstone P, Anbarasu A. Impact of the COVID-19 pandemic on routine vaccine landscape: a global perspective. Hum. Vaccin. Immunother. 19(1), 1–8 (2023).
- Dutt A. Centre writes to states over new Covid variant: all you should know about JN.1 (2023). https://indianexpress.com/article/explained/explained-health/centre-writes-to-states-over-new-covid-variant-all-you-should-know-about-jn-1-9073584/